Overview

Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Status:
Recruiting

Trial end date:
2026-03-13

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to measure how well LY3484356 works compared to hormone therapy in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Exemestane
Fulvestrant